| 干扰素在恶性淋巴瘤自体移植后早期干预的应用 |
| |
| 引用本文： | 薛 慧,刘志彬,冯术青,胡永超,高 峰.干扰素在恶性淋巴瘤自体移植后早期干预的应用[J].现代肿瘤医学,2019,0(11):1992-1994. |
| |
| 作者姓名： | 薛 慧 刘志彬 冯术青 胡永超 高 峰 |
| |
| 作者单位： | 华北理工大学附属医院血液科，河北 唐山 063000 |
| |
| 基金项目： | 2017年政府资助临床医学优秀人才培养和基础课题研究项目 |
| |
| 摘 要： | 目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10～50)个月,患者中位生存时间为37(31～45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。
|
| 关 键 词： | 干扰素 淋巴瘤 自体干细胞移植 干预治疗 |
Application of interferon in early intervention after autologous transplantation of maligant lymphoma |
| |
| Xue Hui,Liu Zhibin,Feng Shuqing,Hu Yongchao,Gao Feng.Application of interferon in early intervention after autologous transplantation of maligant lymphoma[J].Journal of Modern Oncology,2019,0(11):1992-1994. |
| |
| Authors: | Xue Hui Liu Zhibin Feng Shuqing Hu Yongchao Gao Feng |
| |
| Affiliation: | Hematology Department，North China University of Science and Technology Affiliated Hospital，Hebei Tangshan 063000，China. |
| |
| Abstract: | Objective:To observe the clinical effect of early intervention with recombinant human interferon alpha-2b (α-2b IFN)after autologous hematopoietic stem cell transplantation (ASCT)in patients with non-Hodgkin's lymphoma (NHL).Methods:18 cases of NHL were selected as the subjects，and disease assessment before transplantation were not CR.The patients in the trial group were given IFN 3 million U/ alternate day after hematopoietic reconstitution till 3 months，and the control group did not receive interferon treatment.The overall efficacy and survival of the two groups were analyzed.Results:In the median follow-up period of 34（10~50）months，the expected median survival time was 37（31~45）months，and the 3-year progression-free survival (PFS)and overall survival (OS) were 54.7%、66.8%.After ASCT，there was no recurrence in the trial group within 1 year，and the recurrence rate was 12.5% in 2 years.In the control group，the recurrence rate was 20% in 1 years，and 30% in 2 years.Conclusion:Early IFN intervention after ASCT in patients with NHL is well tolerated and may reduce the early recurrence rate. |
| |
| Keywords: | interferon lymphoma autologous stem cell transplantation intervention therapy |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
|
